Inhibition of human telomerase in MKN-45 cell line by antisense hTR expression vector induces cell apoptosis and growth arrest

Run-Hua Feng, Zheng-Gang Zhu, Jian-Fang Li, Bin-Ya Liu, Min Yan, Hao-Ran Yin, Yan-Zhen Lin

INTRODUCTION

Gastric cancer is a very common tumor in China. More and more patients with gastric cancer can now be found in early stage because of the improvement of the technology of diagnosis[36]. Although surgery and chemotherapy are effective for these patients with localized tumors, the prognosis of patients having advanced or metastatic tumors is not ideal[37-40]. As a result, it is absolutely necessary to explore a novel modality of treatment. Fortunately, with the development of molecular biology, medicine is on the brink of a new era- that of molecular genetic medicine. People are now equipped with a new and powerful weapon: gene therapy which was previously only the stuff of dreams and scientific fantasy to fight against disease. Just like other kinds of cancer, the gastric cancer is now recognized as a genetic disease. The gastric cancer cells contain many genetic alterations (caused by some pathogenic agents such as Helicobacter pylori) which accumulate as tumor develops[41-52]. This makes it possible to treat cancer with gene therapy[29-30]. Because the target aimed by the gene therapy is undoubtedly the abnormal gene, thus, the task to find an effective target gene directed against the gene therapy is becoming increasingly important and urgent. Human telomerase is a ribonucleoprotein which can add the telomeric repeats (TTAGGG) to the ends of the chromosome to maintain the telomere length, ensuring chromosome integrity and its nearly ubiquitous characteristic of cancer cell, through the reactivation of telomerase[36,37]. It was reported that HeLa cells transfected with an antisense hTR lost telomeric DNA and began to die after 23 to 26 doublings. Accordiog to a recent review, telomerase activity was inhibited by 75%, the apoptotic rate was increased to 25.3%, the percentage of cells in the G0/G1 phase was increased to 65%, the proliferation index was decreased to 35% and the apoptotic rate was increased to 25.3%. The seemingly essential roles of telomerase in maintaining telomere length, ensuring chromosome integrity and its nearly ubiquitous reactivation in human cancers have made telomerase a new therapeutic target for anticancer therapy[19-21]. It was reported that HeLa cells transfected with an antisense hTR lost telomeric DNA and began to die after 23 to 26 doublings. Accordiog to a recent review, telomerase activity was also detected in 85-88% of gastric carcinomatous tissues. To gastric cancer, hTR was expressed at a higher level in the tumor than that in the corresponding mucosa and tumors with telomerase activity were generally large in size with a high frequency of lymph node metastasis. Moreover, the patients with telomerase-positive tumors shared poorer prognosis than those with telomerase-negative tumors[46-48]. However, whether antisense gene therapy directed against telomerase will be useful in gastric cancer is so far unknown. We describe here the biologic behavior changes in MKN-45 cell line, a human gastric cell line, after transfected with antisense hTR expression vector and investigate the potential value of telomerase as a target for antisense gene therapy in gastric cancer.

Run-Hua Feng, Zheng-Gang Zhu, Jian-Fang Li, Bin-Ya Liu, Min Yan, Hao-Ran Yin, Yan-Zhen Lin. Inhibition of human telomerase in MKN-45 cell line by antisense hTR expression vector induces cell apoptosis and growth arrest. World J Gastroenterol 2002;8(3):436-440

METHODS:
The hTR cDNA fragment was cloned from MKN-45 through RT-PCR and subcloned into eukaryotic expression vector (pEF6/V5-His-TOPO) in cis-direction or trans-direction by DNA recombinit methods. The constructed sense, antisense and empty vectors were transfected into MKN-45 cell lines separately by lipofectin-mediated DNA transfection technology. After drug selection, the expression of antisense hTR gene in stable transfectants and normal MKN-45 cells was detected by RT-PCR, the telomerase activity by TRAP, the apoptotic features by PI and Hoechst 33258 staining, the cell cycle distribution by flow cytometry and the population doubling time by cell counting. Comparison among the stable transfectants and normal MKN-45 cells was made.

RESULTS: The sense, antisense hTR eukaryotic expression vectors and empty vector were successfully constructed and proved to be the same as original design by restriction endonuclease analysis and sequencing. Then, they were successfully transfected into MKN-45 cell lines separately with lipofectin. The expression of antisense hTR gene was only detected in MKN-45 cells stably transfected with antisense hTR vector (named as MKN-45-ahTR) but not in the control cells. In MKN-45-ahTR, the telomerase activity was inhibited by 75%, the apoptotic rate was increased to 25.3%, the percentage of cells in the G0/G1 phase was increased to 65%, the proliferation index was decreased to 35% and the population doubling time was prolonged to 35.3hours. However, the telomerase activity, the apoptotic rate, the distribution of cell cycle, the proliferation index and the population doubling time were not different among the control cells.

CONCLUSION: Antisense hTR can significantly inhibit telomerase activity and proliferation of MKN-45 cells and induce cell apoptosis. Antisense gene therapy based on telomerase inhibition can be a potential therapeutic approach to the treatment of gastric cancer.
**MATERIALS AND METHODS**

**Cell Culture**

MKN-45 cell, a human gastric cancer cell line, was obtained from Shanghai institute of Cell Biology, Chinese Academy of Sciences. The cells were routinely cultured in RPMI-1640 media (Gibco BRL) supplemented with 10% heat-inactivated fetal bovine serum (Gibco BRL), 100μ/ml penicillin and 100μ/ml streptomycin in an atmosphere consisting of 5% CO₂ in air at 37°C in a humidified incubator.

**Construction of sense and antisense hTR eukaryotic expression vector**

The hTR cDNA fragment was cloned from MKN-45 cell line through RT-PCR and subcloned into eukaryotic expression vector: pEF6/V5-His-ToPO vector (Invitrogen) in cis-direction or trans-direction by using DNA recombinant methods as described previously[49]. They were all proved to be the same as original design by restriction endonuclease analysis and sequencing. The sense, antisense and empty vectors were named as pEF-hTR, pEF-ahTR and pEF-empty correspondingly.

**Transfection of eukaryotic expression vector**

Stable transfection of pEF-hTR, pEF-ahTR and pEF-empty was carried out by standard lipofection mediated DNA transfection method. In brief, approximately 1.5×10⁶ MKN-45 cells were transfected with 2μg vector DNA that had been complexed with 20μl lipofectin reagent (Gibco BRL). Two days after the transfection, the stable transfectants were selected by 2μg/ml blasticidin (Invitrogen) in the culture media. They were named as MKN-45-hTR, MKN-45-ahTR and MKN-45-empty correspondingly.

In addition, the pEF6/V5-His-ToPO/lacZ vector (pEF6/V5-His-ToPO vector carrying the reporter gene: lacZ gene in its multi cloning sites, provided by Invitrogen) was transfected into MKN-45 cells and selected by the same method as described above. It was named as MKN-45-lac correspondingly.

**RT-PCR for detecting antisense hTR expression**

Total RNA was extracted from the transfectants and normal MKN-45 cells using Trizol reagent (Gibco BRL). One microgram of total RNA was reverse transcribed with ahTR specific primer1 (5’-gaagggcgagctgctgacct-3’) using THERMOSCRIPT RT-PCR system for first-strand cDNA synthesis (Gibco BRL). The RT condition was set for 65°C, 30min→85°C, 5min. Then, the cDNA was amplified with the PCR using PLATINUM Taq DNA polymerase (Gibco BRL) and employing ahTR specific primer1 and primer2 (5’-gggggggaaatcctgcagct-3’). The PCR conditions were set for 94°C, 2min→94°C, 20s;69°C, 20s;72°C, 20s;30 cycles →72°C,2min. The product length is 196bp.

The G6PDH was co-reversetranscribed empolying G6PDH specific primer1 (5’-gcagcgccctcctggtgcttc-3’) and co-amplified with PCR using G6PDH specific primer1 and primer2 (5’-cgcagccctctgctctgctcct-3’) as internal control. The product length is 247bp. Each RT-PCR product was then electrophoresed in a 12.5% non-denaturing PAGE gel. The product length is 196bp.

**β-Gal staining**

The MKN-45 cells stably transfected with pEF6/V5-His-ToPO/lacZ vector were subjected to β-Gal staining by using β-Gal Staining Kit (Invitrogen) to detect whether the vector could effectively express lacZ gene.

**Apoptotic features**

To determine whether MKN-45-ahTR transfected with the pEF-ahTR vector displayed an apoptotic morphology, it was stained with the DNA binding fluorochrome bis (benzimide) trihydro-chloride, Hoechst 33258 (provided by Shanghai institute of Immunology) and observed under UV fluorescence microscope.

To determine the apoptotic rate and cell cycle distribution, the MKN-45-ahTR and control cells were stained with PI and analysed by flow cytometry.

**RESULTS**

**Expression of antisense hTR gene in MKN-45 cells**

We transfected MKN-45 cells with pEF-hTR, pEF-ahTR and pEF-empty vector respectively, following the blasticidin selection, the drug resistant cells were collected and RT-PCR was performed with antisense hTR specific primers. We detected the ahTR specific product only in the pEF-ahTR vector transfected cells but not in the pEF-hTR, pEF-empty vector transfected cells and parental cells. However, steady state expression of G6PDH (as internal control) was observed in all cells.

**Telomerase activity assay**

Telomerase activity was measured using the commercially available TRAP_eze Telomerase Detection Kit (Intergen). In brief, the cell extract was made according to the protocol provided, then 2μl of the cell extract was added to 48μl of the reaction mixture containing 10× TRAP Reaction Buffer, 50x dNTP Mix, TS Primer, TRAP Primer Mix, Taq Polymerase and dH₂O in amounts and types specified by the TRAP_eze Telomerase Detection Kit. After centrifuged briefly, this mixture was incubated at 30°C for 30min to allow telomerase elongation of the TS primer and then subjected to PCR amplification in a thermal cycler for 35 cycles: 94°C for 30s;95°C for 30s and 72°C for 30s. The product was then electrophoresed on a 12.5% non-denaturing PAGE (without urea). After electrophoresis, the gel was stained with SYBR Green I (Molecular Probes) according to the manufacturer’s instructions.

Quantification of telomerase product was calculated using BIO-RAD Fluor-STM Multimager and the formula (discussed in detail in the TRAP_eze Telomerase Detection Kit instruction booklet).

\[
\text{TPG(units)}=\frac{(x-y)\times100}{(r-y)/c_r}
\]

Abbreviation in the above formula is as follows: TPG, total product generated; \(x\), sample signal; \(r\), heat-inactivated control; \(γ\), 0.1 amole quantitation TSR8 control; \(c\), sample internal standard band; \(ε\), 0.1 amole quantitation TSR8 internal standard band.

**Cell growth curve and population doubling time**

Cells were seeded at a density of 2×10⁵ per 25ml flask in 1.5ml of cell culture media. The number of cells per flask was counted every day for 6 days. The population doubling time of cells transfected with pEF-hTR, pEF-ahTR and pEF-empty and normal MKN-45 cells were calculated and the cell growth curve was drawn.

**Apoptotic features**

To determine whether MKN-45-ahTR transfected with the pEF-ahTR vector displayed an apoptotic morphology, it was stained with the DNA binding fluorochrome bis (benzimide) trihydro-chloride, Hoechst 33258 (provided by Shanghai institute of Immunology) and observed under UV fluorescence microscope.

To determine the apoptotic rate and cell cycle distribution, the MKN-45-ahTR and control cells were stained with PI and analysed by flow cytometry.

**Telomerase activity assay**

Telomerase activity was measured using the commercially available TRAP_eze Telomerase Detection Kit (Intergen). In brief, the cell extract was made according to the protocol provided, then 2μl of the cell extract was added to 48μl of the reaction mixture containing 10× TRAP Reaction Buffer, 50x dNTP Mix, TS Primer, TRAP Primer Mix, Taq Polymerase and dH₂O in amounts and types specified by the TRAP_eze Telomerase Detection Kit. After centrifuged briefly, this mixture was incubated at 30°C for 30min to allow telomerase elongation of the TS primer and then subjected to PCR amplification in a thermal cycler for 35 cycles: 94°C for 30s;95°C for 30s and 72°C for 30s. The product was then electrophoresed on a 12.5% non-denaturing PAGE (without urea). After electrophoresis, the gel was stained with SYBR Green I (Molecular Probes) according to the manufacturer’s instructions.

Quantification of telomerase product was calculated using BIO-RAD Fluor-STM Multimager and the formula (discussed in detail in the TRAP_eze Telomerase Detection Kit instruction booklet).

\[
\text{TPG(units)}=\frac{(x-y)\times100}{(r-y)/c_r}
\]

Abbreviation in the above formula is as follows: TPG, total product generated; \(x\), sample signal; \(r\), heat-inactivated control; \(γ\), 0.1 amole quantitation TSR8 control; \(c\), sample internal standard band; \(ε\), 0.1 amole quantitation TSR8 internal standard band.

**Cell growth curve and population doubling time**

Cells were seeded at a density of 2×10⁵ per 25ml flask in 1.5ml of cell culture media. The number of cells per flask was counted every day for 6 days. The population doubling time of cells transfected with pEF-hTR, pEF-ahTR and pEF-empty and normal MKN-45 cells were calculated and the cell growth curve was drawn.

**RESULTS**

**Expression of antisense hTR gene in MKN-45 cells**

We transfected MKN-45 cells with pEF-hTR, pEF-ahTR and pEF-empty vector respectively, following the blasticidin selection, the drug resistant cells were collected and RT-PCR was performed with antisense hTR specific primers. We detected the ahTR specific product only in the pEF-ahTR vector transfected cells but not in the pEF-hTR, pEF-empty vector transfected cells and parental cells. However, steady state expression of G6PDH (as internal control) was observed in all cells.
β-Gal staining
After drug selection, nearly all MKN-45 cells stably transfected with pEF6/V5-His-TOPO/lacZ vector were stained blue by β-Gal Staining Kit while parental cells were not.

Telomerase activity
We measured telomerase activity of the pEF-hTR, pEF-ahTR and pEF-empty transfected MKN-45 cells and parental cells through TRAP method described above. It was found that the level of telomerase activity in the pEF-ahTR transfected MKN-45 cells was greatly inhibited, compared with that in the parental MKN-45 cells. However, there was no difference between the level of telomerase activity in the pEF-hTR, pEF-empty transfected MKN-45 cells and parental MKN-45 cells.

Cellular effects of telomerase inhibition
As Figures 4, 5 and Table 1 showed, compared with controls cells, the MKN-45-ahTR cell displayed a longer population doubling time, an increased percentage of cells in the G0/G1 phase, a lower cell proliferation index and a higher apoptotic rate, which demonstrated that, through inhibiting telomerase activity, antisense hTR gene transfection could inhibit the proliferative capacity of MKN-45 and induce cell apoptosis.

DISCUSSION
Compared with normal somatic cells, which reach the end of their replicative capacity after a limited number of population doubling and enter a senescence phase, the cancer cells have an unlimited replicative capacity. This important characteristic of cancer, named immortality, is gaining more and more attention, seeing that cancer cells may achieve cellular immortality through only a major pathway: activation of the telomerase[47].

Telomerase is a unique ribonucleoprotein that can synthesize telomeric DNA onto chromosomal ends using a segment of its RNA component (hTR) as a template to compensate for the lose of telomeric repeats (TTAGGG) caused by the so-called “end-replication” problem. Recent Study demonstrated that 758 of 895 (85 %) of malignant tumors but none of 70 normal somatic tissues

Figure 2  The result of β-Gal staining of MKN-45-lac. (×600)

Figure 3A  Detection of telomerase activity with the telomeric repeat amplification protocol (TRAP) assay. A 36bp internal control band present in all samples indicated an appropriate polymerase chain reaction (PCR).

Figure 3B  Comparison of telomerase activity in MKN-45-ahTR and control cells. Compared with control cells, the telomerase activity in MKN-45-ahTR was inhibited by about 75%.

Table 1  Comparison of distribution of cell cycle, cellular proliferation index, apoptotic rate,population doubling time of MKN-45-ahTR and those of control cells

|                  | G0/G1 (%) | S (%) | G2/M (%) | Apoptotic rate (%) | Population doubling time (hours) |
|------------------|-----------|-------|----------|--------------------|----------------------------------|
| MKN-45-ahTR      | 65        | 34.2  | 0.8      | 35                 | 25.3                             |
| MKN-45-hTR       | 55.7      | 37.5  | 6.8      | 44.3               | 23.2                             |
| MKN-45-empty     | 54.1      | 38.4  | 7.5      | 45.9               | 22.7                             |
| normal MKN-45    | 54.7      | 37.8  | 7.5      | 45.3               | 22.9                             |

Figure 4  Hoechst 33258 staining of MKN-45-ahTR. (×600)
The cells undergoing apoptosis demonstrated apoptotic chromatin changes: blebbing, fragmentation and condensation under fluorescence microscope.

Figure 5  Cell growth curve.
expressed telomerase activity. In addition, the level of telomerase activity influences the prognosis of patient to a certain degree. For example, high level of telomerase correlates with poor clinical outcome in neuroblastoma, while patients with metastatic IV-S neuroblastoma without telomerase activity experiences spontaneous regression of tumors. These findings indicate that telomerase plays an important role in carcinogenesis and therefore undoubtedly become the basis of the widely held view of telomerase as a highly selective target for antisense gene therapy of cancer[40].

The RNA component of telomerase (hTR) is crucial to the telomerase activity[42,43]. Human cell lines that expressed hTR mutated in the template region generated the predicted mutant telomerase activity. In addition, recent experiments have shown that antisense gene therapy directed against telomerase RNA component (hTR) could effectively inhibit telomerase activity and induce apoptotic cell death in ovarian cancer, prostate cancer, bladder cancer, malignant gliomas and human breast epithelial cells[35,36]. However, whether such anti-cancer effect can be obtained in human gastric cancer is still unknown. Therefore, we examined the effect of antisense hTR (ahTR) expression on the growth of human gastric cancer cell line:MKN-45 through transfection of an ahTR expression vector.

Given that whether the vector can effectively and stably express the exogenous gene it carries will directly influence the effect of antisense gene therapy. Firstly, we adopted two different methods to detect the expression of exogenous gene by the pEF6/V5-His-TOPO vector before conducting other experimental items. The first one was to detect the expression of reporter gene. pEF6/V5-His-TOPO/lacZ vector is the same as the pEF6/V5-His-TOPO vector except that the former carrying lacZ gene, a kind of widely used reporter gene, in its multi cloning sites. Usually by using â- Gal staining method, the researchers can easily detect the expression of lacZ gene through which they further evaluate the ability of the vector's promoter to express the exogenous gene. We found that nearly all cells stably transfected with pEF6/V5- His-TOPO/lacZ vector were stained blue while control cells were not. Therefore, we believed that pEF6/V5-His-TOPO/lacZ vector could effectively express the exogenous gene (lacZ gene) it carried, so did the pEF6/V5-His-TOPO vector. The second one was to detect the expression of antisense hTR gene directly through RT-PCR method. Only the cells transfected with pEF-ahTR expressing the antisense hTR gene were found. Both the results proved that pEF6/V5-His-TOPO vector could effectively express the exogenous gene, thus laying the solid fundament for the study of following experimental items.

As the results showed, the most significant conclusions we could draw from this study were that telomerase in human gastric cancer cell line: MKN-45 could be inhibited by a vector expressing mRNA without telomerase activity and cell apoptosis was induced after transfection of an ahTR expression vector.

REFERENCES

1. Zhang XY. Some recent works on diagnosis and treatment of gastric cancer. World J Gastroenterol. 1999;5:13
2. Lin YZ, Yin HR, Zhu ZG, Lu W, Li DL, Zhang J. The surgical treatment of gastric cancer in Shanghai. Asian J Surg. 2001;24:258-262
3. Maehara Y, Kakeji Y, Oda S, Takahashi I, Akazawa K, Sugimachi K. Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer. 2000;83:986-991
4. Borie F, Millat B, Finger hut A, Hay JM, Fagniez PL, De Saxce B. Lymphatic involvement in early gastric cancer: prevalence and prognosis in France. Arch Surg. 2000;135:1218-1223
5. Cassignu S, Graziano F, Barni S, Labianca R, Comella G, Casaretto R, Frontini L, Catania V, Baldeelli AM, Catalano G. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer. 2001;84:470-474
6. Valle JW. Adjuvant therapy for gastric cancer—the standard changed? Br J Cancer. 2001;84:875-877
7. Liu HF, Liu WW, Fang DC, Yang SM, Wang RQ. Bas gene expression and its relationship with apoptosis in human gastric carcinoma and precancerous lesions. Shijie Huaren Xinhua Zazhi. 2000;8:665-668
8. Fang DC, Zhou XD, Loo HY, Wang DX, Lu R, Yang SM, Liu WW. Microsatellite instability and loss of heterozygosity of suppressor gene in gastric cancer. Shijie Huaren Xinhua Zazhi. 1999;7:479-481
9. Wang YK, Ma NX, Lou HL, Li Y, Wang L, Pan H, Zhang ZB. Relationship between F53, nm23 protein expression and lymphatic hypoplasia in gastric cancer. Shijie Huaren Xinhua Zazhi. 1999;7:34-36
10. Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol. 2000;157:1299-1304
11. Cui DX, Yan JX, Su CZ. Differentially expressed genes were isolated in gastric carcinoma by optimised differential display PCR. Shijie Huaren Xinhua Zazhi. 1999;7:139-144
12. Zhao Y, Zhang XY, Shi XJ, Hu PZ, Zhang CS, Ma FC. Clinical significance of expressions of P16, p53 genes and PCNA in gastric cancer. Shijie Huaren Xinhua Zazhi. 1999;7:246-248
13. Noguchi T, Muller W, Wirtz HC, Willers R, Gabbert HE. FHIT gene in gastric cancer: association with tumour progression and prognosis. J Pathol. 1999;188:378-381
14. Cui DX, Yan XJ, Zhang L, Zhao JR, Jiang M, Guo YH, Zhang LX, Bai XP, Su CZ. Screening and its clinical significance of 6 fragments of highly expressing genes in gastric cancer and precancerous mucosa. Shijie Huaren Xinhua Zazhi. 1999;7:770-772
15. He XS, Su Q, Chen ZC, He XT, Long ZF, Ling H, Zhang LR. Expression, deletion and mutation of p16 gene in human gastric cancer. World J Gastroenterol. 2001;7:515-521
16. Liu HF, Liu WW, Fang DC, Men RP. Expression and significance of prosapotropic gene Bax in gastric carcinoma. World J Gastroenterol. 1999;5:15-17
17. Wang B, Shi LC, Zhang WB, Xiao CM, Wu JF, Dong YM. Expression and significance of P16 gene in gastric cancer and its precancerous lesions. Shijie Huaren Xinhua Zazhi. 2001;9:39-42
18. Ji F, Peng QB, Zhan JB, Li YM. Study of differential polymerase chain reaction of C-erbB-2 oncogene amplification in gastric cancer. World J Gastroenterol. 1999;5:152-155
19. Guo CQ, Wang YP, Liu GY, Ma SW, Ding GY, Li J. Cancer Study on Helicobacter pylori infection and P53, c-erbB-2 gene expression in carcinogenesis of gastric mucosa. Shijie Huaren Xinhua Zazhi. 1999;7:313-315
20. Chen SY, Wang JY, Ji Y, Zhang XD, Zhub CW. Effects of Helicobacter pylori and protein kinase C on gene mutation in gastric cancer and precancerous lesions. Shijie Huaren Xinhua Zazhi. 1999;7:302-307
21. Zhang Z, Yuan Y, Gao H, Dong M, Wang L, Gony YH. Apoptosis, proliferation and p53 gene expression of H. pylori associated gastric epithelial lesions. World J Gastroenterol. 2001;7:779-782
22. Wang DX, Fang DC, Li W, Du QX, Liu WW. A study on relationship between infection of Helicobacter pylori and inactivation of antioncogenes in cancer and pre-cancerous lesion. Shijie Huaren Xinhua Zazhi. 2001;9:984-987
23. Xu FB, Xu YY, Yan W, Pan BR, Ren J, Fan DM. Association of H. pylori infection with gastric carcinoma: Meta analysis. World J Gastroenterol. 2001;7:801-804
24 Mielke S, Kirsch C, Dragosics B, Gschwantler M, Oberhuber G, Antos D, Dite P, L uter J, Labenz J, Leodolter A, Malferttheiner P, Neubauer A, Ehninger G, Stolle M, Bayerd rffer E. Helicobacter pylori and gastric cancer: current status of the Austrian Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol 2001;7:243-247

25 Liu HF, Liu WW, Fang DC, Yang SM, Zhao L. Gastric epithelial apoptosis induced by Helicobacter pylori and its relationship with Bax protein expression. Shijie Huen xiaohua Zazhi 2000;8:860-862

26 Yamagata H, Kiyohara Y, Asayagi K, Kato I, Iwamoto H, Nakayama K, Shimizu T, Tanizaki Y, Arima H, Shinohara N, Kondo H, Matsumoto T, Fujisima M. Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama stuy. Arch Intern Med 2000;160:1962-1968

27 Zhang ZW, Fehring SA, G. Molecular mechanisms of H. pylori associated gastric carcinogenesis. World J Gastroenterol 1999;5:369-374

28 Yao YL, Xu B, Song YG, Zhang WD. Overexpression of cyclin E in Mongolian gerbil with Helicobacter pylori-induced gastric precancerous. World J Gastroenterol 2002;8:60-63

29 Yu WL, Huang ZH. Progress in studies in gene therapy for gastric cancer. Shijie Huen xiaohua Zazhi 1999;7:887-889

30 Xu CT, Huang LT, Pan BR. Current gene therapy for stomach carcinoma. World J Gastroenterol 2001;7:752-759

31 Chen B, Liu WW, Fang DC. An overview of current studies on telomerase. Shijie Huen xiaohua Zazhi 2001;9:441-446

32 Chen JL, Blasco MA, Greider CW. Secondary structure of vertebrate telomerase RNA. Cell 2000;100:503-514

33 Vasef MA, Ross JS, Cohen MB. Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Am J Clin Pathol 2000;113:447-453

34 Feng DY, Zheng H, Fu CY, Cheng RX. An improvement method for the detection of in situ telomerase activity: in situ telomerase activity labeling. World J Gastroenterol 1999;5:537-540

35 He XX, Wang JL, Wu Jl, Yuan SY, Ai L. Telomerase expression, Hp infection and gastric mucosal carcinogenesis. Shijie Huen xiaohua Zazhi 2000;8:505-508

36 Fu W, Begley JG, Killen MW, Mattson MP. Anti-apoptotic role of telomerase in pheochromocytoma cells. Proc Natl Acad Sci USA 1999;96:6621-6625

37 Wu SH, Ma LP, Jin W, Sui YF. Tumor suppressor gene: P16, p21, PRB and its status and future prospects. Anti-cancer drug des 1999;14:341-347

38 Herbert BS, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR. Inhibition of human telomerase in immortal human cells by antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 2000;60:4461-4467

39 Hahn WC, Stellow SA, Brooks MW, York SG, Eaton E, Kurachi A, Beierserselen RL, Knoll JH, Meyerson M, Weinberg RA. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164-1170

40 Lichtsteiner SP, Lebkowski JS, Vasserot AP. Telomerase, a target for anticancer therapy. Ann N Y Acad Sci 1999;866:1-11

41 Guo Z, Yang SM. A new anti-cancer target point: progress in the studies of telomere and its inhibitors. Shijie Huen xiaohua Zazhi 1999;7:607-609

42 Ma JP, Zhan WH, Cai SR, Peng JS, Wang JP. Telomerase activity in gastric cancer. Chin J Dig 2000;13:16

43 He XX, Wang JL, Wu Jl, Yuan SY, Ai L. Telomere, cellular DNA content and gastric mucosal carcinogenesis. Shijie Huen xiaohua Zazhi 2000;8:509-512

44 Okusa Y, Ichikura T, Mochizuki H, Shinomiya N. Clinical significance of telomerase activity in biopsy specimens of gastric cancer. J Clin Gastroenterol 2000;30:61-63

45 Zhang FX, Deng ZY, Zhang XY, Kang SC, Wang Y, Yu XL, Wang H, Biao XH. Telomeric length associated with prognosis in human primary and metastatic gastric cancer. Shijie Huen xiaohua Zazhi 2000;8:153-155

46 Kakeji Y, Maehara Y, Koga T, Shibahara K, Kabashima A, Tokunaga E, Sugimachi K. Gastric cancer with high telomerase activity shows rapid development and invasiveness. Oncol Rep 2001;8:107-110

47 Guo Z, Yang SM. A new anti-cancer target point: progress in the studies of telomere and its inhibitors. Shijie Huen xiaohua Zazhi 2001;9: 1409-1414

48 Zhang ZW, Fehring SA, G. Molecular mechanisms of H. pylori associated gastric carcinogenesis. World J Gastroenterol 1999;5:369-374

49 Tanaka H, Kiyohara Y, Asayagi K, Kato I, Iwamoto H, Nakayama K, Shimizu T, Tanizaki Y, Arima H, Shinohara N, Kondo H, Matsumoto T, Fujisima M. Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama study. Arch Intern Med 2000;160:1962-1968

50 Vasef MA, Ross JS, Cohen MB. Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Am J Clin Pathol 2000;113:447-453

51 He XX, Wang JL, Wu Jl, Yuan SY, Ai L. Telomerase expression, Hp infection and gastric mucosal carcinogenesis. Shijie Huen xiaohua Zazhi 2000;8:505-508

52 Herbert BS, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR. Inhibition of human telomerase in immortal human cells leads to progressive telomere shorting and cell death. Proc Natl Acad Sci USA 1999;96:14276-14281

53 Wang DX, Fang DC, Liu WW. Study on alteration of multiple genes in intestinal metaplasia, atypical hyperplasia and gastric cancer. Shijie Huen xiaohua Zazhi 2001;8:654-658

54 Okusa Y, Ichikura T, Mochizuki H, Shinomiya N. Clinical significance of telomerase activity in biopsy specimens of gastric cancer. J Clin Gastroenterol 2000;30:61-63

55 Zhang FX, Deng ZY, Zhang XY, Kang SC, Wang Y, Yu XL, Wang H, Biao XH. Telomeric length associated with prognosis in human primary and metastatic gastric cancer. Shijie Huen xiaohua Zazhi 2000;8:153-155

56 Kakeji Y, Maehara Y, Koga T, Shibahara K, Kabashima A, Tokunaga E, Sugimachi K. Gastric cancer with high telomerase activity shows rapid development and invasiveness. Oncol Rep 2001;8:107-110

57 Wu SH, Ma LP, Jin W, Sui YF. Tumor suppressor gene: P16, p21, PRB and its status and future prospects. Anti-cancer drug des 1999;14:341-347

58 Zhang ZW, Fehring SA, G. Molecular mechanisms of H. pylori associated gastric carcinogenesis. World J Gastroenterol 1999;5:369-374

59 Komata T, Kondo Y, Koga S, Ko SC, Chung LWK, Kondo S. Combi-